Antiaging Quantum Living Inc (AAQL)

[oc631]

Dew is WRONG! ACHN is very relevant indeed!

You support your case with cut and paste company BS. If ACHN is so confident in their nuke (ACH-3422) why are they considering testing it in a 3-DAA oral combination with a protease inhibitor? GILD only needs one DAA (GT2/GT3) or two (GT1), can be dosed for 8-weeks in many patients, and they are years ahead of ACHN. This is a Hail Mary pass by ACHN to achieve 8-week dosing with a potentially unsafe combination (unstable PK profile?, look at ACH-2684 abstracts) . There's no guarantee ACH-3422 will reach the clinic yet if it does that's when the IP challenges will come into play. Why do you think large pharma isn't working on HCV compounds within the nucleotide analog class? Not enough money to be made there?


You need to know the difference between creative writing and clinical achievement. Here's some more questions for you

-Why are they still without a partner?

-What happens when ACHN needs to run non-inferiority studies against Sovaldi? How much will that cost?

Meanwhile the HCV market will eventually move to "diagnose and treat". Every patient in developed markets (beyond treatment-failures) will need to be found (newly diagnosed) before making a treatment decision.